The use of dulaglutide in real clinical practice in patients with type 2 diabetes mellitus in Moscow

Objective. Evaluation of the effectiveness of dulaglutide in real clinical practice for patients with type 2 diabetes mellitus (DM2) in Moscow.

Methods. To assess the main indicators of DM2 patients using dulaglutide in therapy, a sample was formed from the Moscow segment of the Federal Register of Diabetes Mellitus (FRDM) as of 02/14/2024. To assess the effectiveness of dulaglutide therapy over a 5-year follow-up period, an additional sample of patients from the Moscow segment of the FRDM who began treatment with dulaglutide in 2018 was formed.

Results. When assessing the dynamics of carbohydrate metabolism control indicators over a more than 5-year follow-up period (2018–02/01/2024), a trend towards a decrease in HbA1c levels from 7.3 to 7.0% was noted (p>0.05). In the subgroup of patients who did not receive insulin therapy, a statistically significant decrease in HbA1c levels from 7.3 to 6.7% was demonstrated (p=0.04); there was no statistically significant change in HbA1c levels on insulin therapy (7.5±1.1 versus 7.7±1.1%; p>0.05). When assessing the dynamics, a statistically significant decrease in body weight from 102.9±21.8 to 98.4±19.6 kg, a decrease in body mass index (BMI) from 35.6 to 33.5 kg/m² (p<0.05) primarily in patients who did not receive insulin therapy (p<0.05) was noted. In patients on insulin therapy, there were no statistically significant differences in the dynamics of body weight and BMI.

Conclusion. The use of dulaglutide in real clinical practice demonstrates long-term maintenance of glycemic control indicators within or close to target values and a statistically significant reduction in body weight and BMI. The greatest effectiveness in achieving glycemic control, reducing body weight and BMI was achieved in a cohort of DM2 patients not receiving insulin medications.